Evidence map›Paper›PMID 34671342›Full record

ReviewFrontiers in immunology2021

Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.

Steven K Yarmoska, Ali M Alawieh, Stephen Tomlinson, Kimberly B Hoang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Steven K YarmoskaDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States.
Ali M AlawiehDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States.
Stephen TomlinsonDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
Kimberly B HoangDepartment of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal MetastasesF30CA216939 · NCI · EMORY UNIVERSITY · PI YARMOSKA, STEVEN KARL · 2017 to 2021
$250k
BLRD VA IK6 BX005235NCI NIH HHS F30 CA216939NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

The complement system is a highly conserved component of innate immunity that is involved in recognizing and responding to pathogens. The system serves as a bridge between innate and adaptive immunity, and modulation of the complement system can affect the entire host immune response to a foreign insult. Neoplastic diseases have been shown to engage the complement system in order to evade the immune system, gain a selective growth advantage, and co-opt the surrounding environment for tumor proliferation. Historically, the central nervous system has been considered to be an immune-privileged environment, but it is now clear that there are active roles for both innate and adaptive immunity within the central nervous system. Much of the research on the role of immunological modulation of neoplastic disease within the central nervous system has focused on adaptive immunity, even though innate immunity still plays a critical role in the natural history of central nervous system neoplasms. Here, we review the modulation of the complement system by a variety of neoplastic diseases of the central nervous system. We also discuss gaps in the current body of knowledge and comment on future directions for investigation.

Indexed as

NeuroimmunomodulationAdaptive ImmunityAnimalsCentral Nervous SystemCentral Nervous System NeoplasmsComplement System ProteinsHumansImmunity, InnatePrognosisSignal TransductionComplement System Proteinsbraincancercomplementglioblastomagliomaleptomeningealmetastasisradiation

Identifiers

PMID34671342
PMCPMC8521155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.